IMMUNIC, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | 0.00% |
|
-1.57% | -16.67% |
| May. 08 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechJessica Breu (Executives)Good morning, and welcome to Immunic Inaugural R&D me...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Calendar
2024-06-11
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.25
USD
Average target price
11.5
USD
Spread / Average Target
+820.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 113M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Transcript : Immunic, Inc. - Special Call
